# ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab

> clinical trial · VERIFIED · 2026-08-24

Status: RECRUITING · Sponsor: NYU Langone Health · Condition: Metastatic Melanoma

- Company: NYU Langone Health
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07504796

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.